Angelica Peebles talked to Dave Ricks about the news and joins us now. Hey Angelica. >> Hey Carl.Well, Lily is revealing the first of four new US manufacturing sites and it will be in Virginia. So this $5 billion site will specialize in making active pharmaceutical ingredients and drug product for Lily's cancer and autoimmune disease medicines as well as other advanced therapies. So the new factory will give Lily the ability to make targeted chemotherapies or antibody drug conjugates for the first time.And ...

Core Insights - EUROAPI released its 2025 condensed Half-Year Consolidated Financial Statements for the six months ending June 30, 2025, available on its website [1][2] - The company focuses on reinventing active ingredient solutions to meet global customer and patient needs, with a portfolio of approximately 200 products [3] - EUROAPI operates five manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] Financial Overview - The report includes the 2025 half-year management report and the consolidated financial statements as of June 30, 2025 [2] - The Statutory Auditors' review report on the half-yearly financial information is also part of the documentation [2] Company Profile - EUROAPI is a leading player in active pharmaceutical ingredients, developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company employs approximately 3,270 individuals dedicated to enabling access to essential therapies [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]

Group 1 - Euroapi S.A. announced financing from the European Commission and a plan to reorganize its business structure to enhance efficiency in the active pharmaceutical ingredient market [1] - The company operates in a growing sector, indicating potential for future growth and investment opportunities [1] - The analyst has a beneficial long position in the shares of Euroapi S.A., reflecting confidence in the company's prospects [2] Group 2 - The article emphasizes the importance of understanding business models before investing, highlighting a cautious approach to investment [1] - The analyst's experience spans various financial sectors, which may provide valuable insights into the company's performance and market trends [1]

Core Points - The Combined General Shareholders' Meeting of EUROAPI was held on May 21, 2025, in Paris, where all resolutions proposed by the Board of Directors were approved by shareholders [1][2] - The meeting included the approval of the unconsolidated and consolidated financial statements for the year 2024, compensation arrangements for corporate officers, and financial authorizations [2] - EUROAPI's Board of Directors now consists of ten members, with a majority being independent directors, including five independent members and two employee representatives [2] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, being a leading player in active pharmaceutical ingredients with around 200 products in its portfolio [3][4] - The company operates six manufacturing sites in Europe and employs approximately 3,430 people, ensuring high-quality API manufacturing for customers in over 80 countries [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI and has strong research and development capabilities [4]

Company Information - EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs globally, being a leading player in active pharmaceutical ingredients with approximately 200 products in its portfolio [5] - The company has strong research and development capabilities and operates six manufacturing sites located in Europe, ensuring high-quality API manufacturing to supply customers in over 80 countries [6] - EUROAPI is listed on Euronext Paris with ISIN: FR0014008VX5 and ticker: EAPI [6] General Meeting Details - Shareholders are invited to the Combined General Meeting on May 21, 2025, at 10:30 a.m. (CET) in Paris [1] - The notice of the meeting was published in the French official legal announcement publication on April 16, 2025, and in Actu-juridique.fr on April 28, 2025 [1] - Documents related to the General Meeting are available on the company's website under the "Annual General Meeting 2025" section [2] Shareholder Communication - Registered shareholders can request additional documents via email or at the company's registered office, with documentation sent by post or email depending on their preference [3] - Shareholders are encouraged to regularly check the company's website for the latest information regarding the Annual General Meeting, which will be broadcast live unless technical issues arise [4]

Group 1 - Orion Corporation has received a notification regarding transactions made by its Chief Financial Officer, René Lindell, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 4,533 shares at a unit price of 0 EUR [1] - Orion Corporation's net sales in 2024 amounted to EUR 1,542 million, and the company employed approximately 3,700 people at the end of the year [2] Group 2 - Orion Corporation is a Finnish pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain management [2] - Orion's shares are listed on Nasdaq Helsinki, with both A and B shares available for trading [2]